MarketCap
Facebook
X
Telegram
C4 Therapeutics Financial Ratios 2025-2011 | CCCC
Brief overview of C4 Therapeutics's multiples and efficiency
Ratios are assessed across five available annual reports in the 2021–2025 interval.
Key multiples at the end of the period are P/S 6.5x (median 9.63x), P/B 0.91x (median 1.04x). Valuation is roughly 22.3% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
End-period return metrics are ROE -40.9%, ROA -29.2%, ROCE -44.9%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
Price, earnings and growth produce a PEG of 0.24x. A value below one indicates moderate pricing relative to expected growth.
A shorter cycle, from 40.7 days to 27.9 days, indicates faster release of cash from operations.
Overall picture
C4 Therapeutics's restrained price comes with modest current quality. Better efficiency is needed for revaluation.
Annual Financial Ratios C4 Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-2.2 | -1.7 | -3.3 | -2.3 | -17.7 | -22.2 | - | - | - | - | - | - | - | - | - |
P/S |
6.5 | 5.1 | 21.1 | 9.6 | 32.4 | 44.4 | - | - | - | - | - | - | - | - | - |
EPS |
-1.3 | -1.5 | -2.7 | -2.6 | -1.8 | -5.8 | -31.0 | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
262 M | 261 M | 442 M | 411 M | 1.52 B | 1.41 B | 140 M | 187 M | - | - | - | - | - | - | - |
EBITDA per Share |
-1.37 | -1.7 | -2.76 | -2.62 | -1.75 | -1.44 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-2.3 | -2.2 | -3.2 | -3.2 | -18.8 | -22.1 | - | - | - | - | - | - | - | - | - |
PEG |
-0.6 | - | - | - | - | 0.24 | - | - | - | - | - | - | - | - | - |
P/B |
0.9 | 0.8 | 1.8 | 1.0 | 3.8 | 5.2 | - | - | - | - | - | - | - | - | - |
P/CF |
-2.4 | -2.8 | -4.1 | -2.8 | -17.0 | -21.7 | - | - | - | - | - | - | - | - | - |
ROE % |
-40.92 | -48.76 | -53.83 | -44.32 | -21.53 | -23.62 | - | - | - | - | - | - | - | - | - |
ROA % |
-29.24 | -30.12 | -35.20 | -29.75 | -16.55 | -16.58 | - | - | - | - | - | - | - | - | - |
ROCE % |
-44.91 | -55.38 | -56.49 | -44.79 | -21.08 | -16.97 | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.5 | 2.6 | 2.9 | 3.0 | 4.3 | 8.7 | - | - | - | - | - | - | - | - | - |
DSO |
27.9 | 76.4 | 116.7 | 42.2 | 40.7 | 49.3 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
27.9 | 76.4 | 116.7 | 42.2 | 40.7 | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
27.9 | 76.4 | 116.7 | 42.2 | 40.7 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios C4 Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.37 | -0.2 | - | -0.44 | -0.37 | -0.37 | - | -0.35 | -0.26 | -0.41 | - | -0.55 | -0.73 | -0.71 | - | -0.65 | -0.56 | -0.65 | - | -0.51 | -0.51 | -0.49 | - | -17.55 | -9.28 | -9.59 | - | -8.93 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.4 | -0.22 | - | -0.47 | -0.4 | -0.41 | - | -0.4 | -0.31 | -0.46 | - | -0.56 | -0.76 | -0.73 | - | -0.66 | -0.55 | -0.64 | - | -0.49 | -0.5 | -0.47 | - | -11.6 | -7.07 | -8.15 | - | -6.41 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-58.69 | -60.00 | -49.27 | -59.43 | -45.77 | -41.81 | -28.32 | -40.83 | -46.04 | -52.12 | -41.14 | -51.18 | -46.62 | -39.92 | -26.67 | -32.86 | -28.24 | -28.24 | -19.56 | -27.34 | -24.99 | -23.81 | -15.86 | -6.85 | -3.84 | -4.24 | - | 9.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-35.86 | -36.77 | -29.13 | -35.69 | -28.22 | -26.56 | -18.33 | -26.45 | -29.47 | -33.60 | -26.48 | -33.41 | -31.42 | -26.70 | -17.92 | -22.19 | -15.27 | -20.87 | -14.74 | -20.20 | -18.03 | -16.74 | -11.13 | -19.67 | -2.70 | -2.98 | - | -8.54 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-63.72 | -65.47 | -53.61 | -65.24 | -51.64 | -47.74 | -32.79 | -45.67 | -50.10 | -55.22 | -42.75 | -52.96 | -48.03 | -40.57 | -26.76 | -32.84 | -27.95 | -27.78 | -19.17 | -25.70 | -23.49 | -22.57 | -14.80 | -5.86 | -3.87 | -4.39 | - | 8.93 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.5 | 3.5 | 2.6 | 2.4 | 2.4 | 2.6 | 2.6 | 2.8 | 2.8 | 2.8 | 2.9 | 2.9 | 2.6 | 3.0 | 3.0 | 3.2 | - | 3.4 | 4.3 | 4.7 | 4.7 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 1.0 | 1.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
37.3 | 44.4 | - | 35.4 | 71.9 | 70.2 | - | 34.2 | 56.1 | 381.3 | - | 6.3 | 26.6 | 24.3 | - | 10.1 | 5.8 | 44.6 | - | 59.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 35.4 | 71.9 | 70.2 | - | 34.2 | 56.1 | 381.3 | - | 6.3 | 26.6 | 24.3 | - | 10.1 | 5.8 | 44.6 | - | 59.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 35.4 | 71.9 | 70.2 | - | 34.2 | 56.1 | 381.3 | - | 6.3 | 26.6 | 24.3 | - | 10.1 | 5.8 | 44.6 | - | 59.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company C4 Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
France
Germany
Israel
Britain
Russia
Belgium
Cayman-islands
